XSHG
603658
Market cap2.92bUSD
Dec 05, Last price
36.15CNY
1D
0.64%
1Q
-10.85%
Jan 2017
-34.97%
IPO
56.49%
Name
Autobio Diagnostics Co Ltd
Chart & Performance
P/E
17.29
P/S
4.62
EPS
2.09
Div Yield, %
2.91%
Shrs. gr., 5y
1.11%
Rev. gr., 5y
10.78%
Revenues
4.47b
+0.62%
Net income
1.19b
-1.89%
CFO
1.31b
-10.92%
Dividend
Jun 05, 20241.05208 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Autobio Diagnostics Co., Ltd. engages in the research and development, production, and distribution of clinical diagnostic products. It develops immunoassay, biochemistry, microbiology, and IVD reagents; and instruments, such as automation and semi-automation systems, as well as medical laboratory solutions. The company's immunoassay products AutoLumo A2000 Plus, an automatic Chemiluminescence immunoassay analyzer; automatic microplate chemiluminescent enzyme immunoassay; and LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Its microbiology products comprise automated blood culture systems; blood culture bottles; AUTOMIC strips; and mycoplasma IES. The company was formerly known as Lifeclone Diagnostics Co., Ltd. and changed its name to Autobio Diagnostics Co., Ltd. in 2003. Autobio Diagnostics Co., Ltd. was founded in 1998 and is based in Zhengzhou, China. Autobio Diagnostics Co., Ltd. is a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||